AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)), AstraZeneca ((DE:ZEGA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca, in collaboration with Parexel, is launching a Phase III clinical trial titled A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02). The study aims to evaluate the effectiveness of Saruparib in improving metastases-free survival in men with high-risk prostate cancer with a BRCA mutation.
The study will test Saruparib, an oral drug, in combination with standard treatments like Androgen Deprivation Therapy (ADT) and Abiraterone, against a placebo. The goal is to determine if adding Saruparib can enhance treatment outcomes for patients.
This randomized, double-blind study will involve approximately 700 participants divided into two cohorts. The study uses a parallel intervention model and quadruple masking to ensure unbiased results, focusing primarily on treatment efficacy.
The study is set to begin on July 15, 2025, with an estimated completion date yet to be announced. The last update was submitted on July 10, 2025, indicating the study is on track to start recruitment soon.
For investors, this study represents a significant potential for AstraZeneca to strengthen its oncology portfolio, particularly in the competitive prostate cancer market. Positive results could enhance stock performance and investor confidence, especially given the high stakes in targeting BRCA-mutated cancers.
The study is ongoing, with further details available on the ClinicalTrials portal.